Royalty Pharma Management
Management criteria checks 3/4
Royalty Pharma's CEO is Pablo Legorreta, appointed in Jan 1996, has a tenure of 28.92 years. directly owns 0.83% of the company’s shares, worth $121.22M. The average tenure of the management team and the board of directors is 2.2 years and 4.5 years respectively.
Key information
Pablo Legorreta
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 28.9yrs |
| CEO ownership | 0.8% |
| Management average tenure | 2.2yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt
Dec 05
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)
Nov 13Royalty Pharma: Massive Opportunity Ahead
Nov 09Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21
Oct 14Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)
Oct 09Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Aug 22Royalty Pharma: Busy Putting Capital To Work
Aug 11Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21
Jul 22Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Apr 28Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares
Apr 25Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem
Feb 22Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21
Jan 31Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion
Dec 26Royalty Pharma to co-fund development of schizophrenia drug with Merck
Oct 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$673m |
| Mar 31 2024 | n/a | n/a | US$799m |
| Dec 31 2023 | n/a | n/a | US$1b |
| Sep 30 2023 | n/a | n/a | US$184m |
| Jun 30 2023 | n/a | n/a | US$255m |
| Mar 31 2023 | n/a | n/a | US$332m |
| Dec 31 2022 | n/a | n/a | US$43m |
| Sep 30 2022 | n/a | n/a | US$507m |
| Jun 30 2022 | n/a | n/a | US$466m |
| Mar 31 2022 | n/a | n/a | US$602m |
| Dec 31 2021 | US$50m | US$8m | US$620m |
| Sep 30 2021 | n/a | n/a | US$783m |
| Jun 30 2021 | n/a | n/a | US$972m |
| Mar 31 2021 | n/a | n/a | US$493m |
| Dec 31 2020 | US$56m | n/a | US$495m |
| Sep 30 2020 | n/a | n/a | US$2b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$29m | n/a | US$2b |
Compensation vs Market: Insufficient data to establish whether Pablo's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Pablo's compensation has been consistent with company performance over the past year.
CEO
Pablo Legorreta (60 yo)
28.9yrs
Tenure
Mr. Pablo Gerardo Legorreta serves as Chairman of the Board at ProKidney Corp. He is a Co-Founder & Director of Sequel Med Tech, LLC. He serves as the Chief Executive Officer and Co-Founder at RP Managemen...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.9yrs | no data | 0.83% $ 121.2m | |
| Executive VP & CFO | no data | US$4.56m | 0.19% $ 27.8m | |
| Executive VP of Investments & Chief Legal Officer | 2.2yrs | US$4.56m | 0.24% $ 35.6m | |
| Vice Chairman & Executive VP | 4.7yrs | US$4.56m | 0.083% $ 12.2m | |
| Executive Vice President of Research & Investments | 4yrs | US$4.56m | 0.015% $ 2.2m | |
| Executive Vice President of Investments & General Counsel | 2.2yrs | no data | no data | |
| Executive Vice President of Investments | 1.7yrs | no data | no data | |
| Senior VP & Chief Accounting Officer | no data | no data | no data | |
| Senior VP & Chief Technology Officer | 1.3yrs | no data | no data | |
| Executive VP of Investments & Chief Scientific Officer | 4yrs | US$3.40m | no data | |
| Senior VP and Head of Investor Relations & Communications | no data | no data | no data | |
| Executive VP & Head of Human Capital | less than a year | no data | no data |
2.2yrs
Average Tenure
55yo
Average Age
Experienced Management: RPRX's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.9yrs | no data | 0.83% $ 121.2m | |
| Independent Director | 2.5yrs | US$389.77k | 0.0037% $ 543.3k | |
| Independent Director | 4.4yrs | US$389.77k | 0.0083% $ 1.2m | |
| Independent Director | 4.5yrs | US$389.77k | 0.015% $ 2.1m | |
| Lead Independent Director | 4.4yrs | US$389.77k | 0.023% $ 3.4m | |
| Independent Director | 4.5yrs | US$389.77k | 0.015% $ 2.1m | |
| Independent Director | 4.5yrs | US$389.77k | 0.011% $ 1.7m | |
| Independent Director | 4.5yrs | US$389.77k | 0.0077% $ 1.1m |
4.5yrs
Average Tenure
65.5yo
Average Age
Experienced Board: RPRX's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Royalty Pharma plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Charlie Yang | BofA Global Research |
| Jason Matthew Gerberry | BofA Global Research |